Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Marketed in the U.S. since 2012 for hypercortisolism; authorized generic version launched June 2024.
Relacorilant
Approved · ActiveModality: small molecule
Aliases Lifyorli
Target glucocorticoid receptor (GR)
Partnerships University of Chicago: randomized placebo-controlled Phase 2 of relacorilant + enzalutamide in prostate cancer (pre-prostatectomy), licensed patents. ARCAGY-GINECO: Phase 2 STELLA trial of relacorilant + nab-paclitaxel in 50 cervical cancer patients
Indications
Hypercortisolism(Phase 3)
Platinum-resistant ovarian cancer (with nab-paclitaxel)(Approved)
Pancreatic cancer (with nab-paclitaxel + gemcitabine)(Phase 2)
Cervical cancer (with nab-paclitaxel)(Phase 2)
Prostate cancer (with enzalutamide)(Phase 2)
Other solid tumors(Phase 2)
Catalysts
— fourth quarter of 2026
Status note Hypercortisolism: NDA submitted December 2024; FDA issued Complete Response Letter December 30, 2025. Approved as Lifyorli in March 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer. Phase 2 trials: BELLA (ovarian, Part A enrollment completed December 2025), TRIDENT (pancreatic, initiated December 2025), STELLA (cervical, initiating Q1 2026).
Nenocorilant
Stage not disclosed · ActiveModality: small molecule
Target glucocorticoid receptor (GR)
Indications
Cancer (with immunotherapy)(Stage not disclosed)
Status note Proprietary selective cortisol modulator; trial stage not stated in excerpts.
Miricorilant
Phase 2 · ActiveModality: small molecule
Target glucocorticoid receptor (GR)
Indications
MASH(Phase 2)
Status note Selective cortisol modulator for MASH. Phase 1b completed; randomized double-blind placebo-controlled Phase 2 initiated October 2023.
Dazucorilant
Phase 2 · ActiveModality: small molecule
Target glucocorticoid receptor (GR)
Indications
ALS(Phase 2)
Status note Selective cortisol modulator for ALS; FDA Fast Track Designation and orphan drug status. Phase 2 DAZALS (249 patients, 24 weeks) did not meet its primary endpoint. No discontinuation language in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.